艾迪注射液聯合化療治療晚期卵巢惡性腫瘤的臨床研究

藍國槐　謝岳云　王世坤

【摘要】 目的：研究艾迪注射液聯合化療治療晚期卵巢惡性腫瘤的臨床效果。方法：選擇2014年6月-2016年4月于筆者所在醫院就診的晚期卵巢惡性腫瘤患者共58例，按進入醫院的編號分為觀察組和對照組，每組29例。對照組進行單純的藥物化療治療，觀察組進行艾迪注射液聯合化療治療，比較兩組患者的治療效果和毒性反應。結果：觀察組總有效率68.96%，對照組總有效率41.37%，觀察組總有效率明顯高于對照組，差異有統計學意義（P<0.05）；觀察組的毒性反應發生率明顯低于對照組，差異有統計學意義（P<0.05）。結論：在進行晚期卵巢惡性腫瘤治療時，進行艾迪注射液聯合化療治療能夠明顯增強治療效果，提高患者的生存質量，值得臨床應用與推廣。

【關鍵詞】 艾迪注射液； 聯合化療； 晚期卵巢惡性腫瘤； 臨床研究

doi：10.14033/j.cnki.cfmr.2017.6.003 文獻標識碼 A 文章編號 1674-6805（2017）06-0005-02

Clinical Research of Addie Injection Combined with Chemotherapy in the Treatment of Advanced Malignant Ovarian Tumor/LAN Guo-huai，XIE Yue-yun，WANG Shi-kun.//Chinese and Foreign Medical Research，2017，15（6）：5-6

【Abstract】 Objective：To study the clinical effect of Addie Injection combined with chemotherapy in the treatment of advanced ovarian cancer.Method：A total of 58 patients with advanced malignant ovarian tumor who were admitted to our hospital from June 2014 to April 2016 were divided into the observation group and the control group according to the number of the patients in the hospital，29 cases in each group.The control group was treated with chemotherapy alone，the observation group was treated with Addie Injection combined with chemotherapy，and the therapeutic effect and toxicity of the two groups were compared.Result：The total efficiency rate of the observation group was 68.96%，in the control group，the total efficiency rate was 41.37%，the total efficiency rate of the observation group was significantly higher than that of the control group，the difference was statistically significant（P<0.05）.The incidence rate of the toxic reaction of the observation group was significantly lower than that of the control group，the difference was statistically significant（P<0.05）.Conclusion：In patients with advanced ovarian cancer，Addie Injection combined with chemotherapy treatment can significantly enhance the therapeutic effect，improve the survival of patients，which is worthy of clinical application and promotion.

【Key words】 Addie Injection； Combined chemotherapy； Advanced malignant ovarian tumor； Clinical research

First-authors address：The 181 Hospital of the Chinese Peoples Liberation Army，Guilin 541002，China

卵巢惡性腫瘤又稱卵巢癌，主要是發生在女性卵巢上的腫瘤，是女性生殖器比較常見的腫瘤之一，死亡率在女性惡性腫瘤中的死亡率最高[1]，嚴重威脅著婦女的生命。近年來雖然在卵巢惡性腫瘤的基礎研究和臨床治療方面都已經取得巨大的進展，但是由于治療難度大、臨床效果差，就使得在短時間內晚期卵巢惡性腫瘤患者的生存率仍然沒有很大的提高[2]。目前臨床上治療治療晚期卵巢惡性腫瘤的方法主要是依靠活性植物抗癌藥物，來延長患者的生命。本次研究的主要目的是研究艾迪注射液聯合化療治療晚期卵巢惡性腫瘤的臨床效果，選取了2014年6月-2016年4月于筆者所在醫院就診的晚期卵巢惡性腫瘤患者共58例，以其作為分析的對象，觀察組進行艾迪注射液聯合化療治療，療效顯著，研究的具體情況及各項數據如下。……